current
vaccin
therapeut
prophylact
approv
prevent
treat
diseas
result
ebola
viru
ebov
infect
two
largest
record
outbreak
ebola
viru
diseas
evd
includ
recent
ebola
viru
outbreak
western
africa
ongo
outbreak
democrat
republ
congo
illustr
critic
need
develop
approv
medic
countermeasur
countermeasur
could
potenti
treat
patient
suspect
evd
prevent
develop
diseas
follow
known
exposur
protect
risk
possibl
exposur
famili
member
health
care
worker
laboratori
support
staff
work
control
evd
outbreak
patient
suspect
evd
provid
support
care
standard
therapi
treat
infect
similar
onset
symptom
eg
malaria
typhoid
fever
preval
world
health
organ
recommend
patient
suspect
evd
treat
antimalari
empir
malaria
diagnost
avail
test
result
august
ebola
treatment
center
liberia
short
suppli
standard
antimalari
combin
drug
artemetherlumefantrin
use
patient
suspect
evd
result
patient
confirm
evd
prescrib
antimalari
combin
drug
contain
compound
artesun
amodiaquin
aq
recent
studi
evalu
compar
outcom
evd
patient
prescrib
artesunateamodiaquin
asaq
receiv
patient
prescrib
asaq
lower
risk
death
rel
group
patient
treat
artemetherlumefantrin
patient
admit
treatment
center
within
span
confirm
evd
obviou
chang
care
period
anoth
retrospect
studi
perform
data
ebola
treatment
center
liberia
sierra
leon
also
show
trend
toward
decreas
mortal
evd
patient
receiv
artemeth
deriv
artemisinin
potenti
benefici
antiebov
effect
observ
asaq
could
possibl
attribut
chang
lumefantrin
aq
altern
improv
respons
might
attribut
advers
effect
lumefantrin
evd
patient
rather
improv
treatment
aq
identifi
potent
ebov
inhibitor
multipl
vitro
aq
rapidli
metabol
activ
metabolit
desethylamodiaquin
deaq
follow
oral
administr
aq
metabolit
deaq
known
vitro
antivir
activ
report
antivir
activ
activ
ebov
aq
vitro
activ
ebov
character
detail
evalu
relev
diseas
model
nonhuman
primat
nhp
perform
aq
efficaci
mouseadapt
ebov
maebov
howev
dose
mgkg
bid
rout
administr
intraperiton
differ
treatment
regimen
use
human
patient
addit
ebov
infect
mous
model
use
maebov
mimic
aspect
human
diseas
rash
coagul
hemorrhag
manifest
therefor
countermeasur
treatment
prevent
ebov
infect
appropri
evalu
relev
anim
model
prior
use
human
cynomolgu
rhesu
macaqu
model
previous
shown
mimic
mani
critic
aspect
human
filoviru
evalu
efficaci
aq
rhesu
macaqu
model
evd
oral
administ
use
similar
dose
regimen
use
human
patient
aq
administ
consecut
cours
mgkg
free
base
mgkg
amodiaquin
hydrochlorid
treatment
began
day
ebov
exposur
day
postexposur
studi
found
aq
vivo
efficaci
treatment
evd
rhesu
macaqu
antimalari
treatment
asaq
administ
evd
patient
coformul
artesun
amodiaquin
aq
aq
rapidli
metabol
liver
dihydroartemisinin
dha
desethylamodiaquin
deaq
respect
prior
vivo
evalu
drug
asaq
compon
metabolit
character
inhibitori
effect
ebov
makona
variant
ebovmak
replic
cell
cultur
tabl
data
confirm
previou
report
aq
metabolit
deaq
block
ebov
replic
similar
activ
huh
vero
cell
line
primari
human
macrophag
aq
deaq
exhibit
elev
cytotox
preclud
interpret
antivir
activ
contrast
activ
metabolit
dha
weak
undetect
combinatori
test
aq
metabolit
deaq
dha
reveal
vitro
synergist
effect
ebov
replic
data
shown
base
vitro
data
decis
made
evalu
aq
nhp
model
ebov
infect
object
studi
treat
nhp
aq
dose
regimen
similar
use
evd
patient
ebola
treatment
center
treatment
consist
cours
asaq
dose
determin
accord
age
patient
dose
rang
aq
human
mgkg
correspond
rhesu
macaqu
equival
dose
rang
mgkg
base
bodi
surfac
pharmacokinet
pk
studi
rhesu
macaqu
group
male
femal
perform
monitor
plasma
concentr
aq
fig
activ
metabolit
deaq
fig
studi
evalu
three
daili
oral
dose
aq
use
mgkg
mgkg
pharmacokinet
determin
collect
blood
sampl
hour
h
follow
dose
day
day
fig
day
dose
mgkg
healthi
male
femal
macaqu
aq
welltoler
higher
dose
mgkg
result
varieti
clinic
observ
includ
hypoact
shiver
muscl
tremor
andor
diarrhea
extrem
hypoact
observ
singl
male
mgkg
group
resolv
dose
ceas
anim
mgkg
mgkg
group
lower
blood
pressur
read
predos
dose
day
typic
andor
h
postdos
clinic
chemistri
hematolog
paramet
dose
analyz
fell
within
normal
rang
except
liver
enzym
alanin
aminotransferas
alt
aspart
aminotransferas
ast
elev
day
h
dose
increas
alt
ast
seen
male
femal
anim
mgkg
dose
regimen
though
chang
doserel
increas
consid
toxicolog
signific
aq
metabolit
deaq
reach
peak
concentr
h
tmax
administr
day
day
dose
supplementari
tabl
elimin
phase
halflif
vari
among
individu
anim
rang
h
aq
h
deaq
plasma
concentr
metabolit
deaq
higher
concentr
parent
drug
result
auclast
aucinf
valu
higher
deaq
aq
mgkg
aq
dose
result
cmax
aq
ngml
deaq
ngml
similar
rang
report
mgkg
dose
human
aq
cmax
ngml
deaq
cmax
ngml
base
result
pharmacokinet
studi
mgkg
aq
dose
chosen
studi
evalu
vivo
effect
aq
nhp
model
evd
studi
outlin
supplementari
fig
rhesu
macaqu
challeng
intramuscularli
im
target
dose
plaqueform
unit
pfu
ebovmak
measur
dose
pfu
studi
day
control
group
n
femal
male
receiv
vehicl
treatment
day
postexposur
treatment
group
n
femal
male
receiv
cours
mgkg
aq
oral
administr
day
exposur
ebov
treatment
group
n
femal
male
receiv
cours
mgkg
aq
oral
administr
day
exposur
ebov
anim
euthan
succumb
diseas
day
postexposur
fig
median
time
disposit
day
placebo
treatment
group
day
treatment
group
signific
differ
placebo
treatment
group
versu
treatment
group
p
respect
anim
group
becam
febril
day
postexposur
follow
mark
decreas
bodi
temperatur
preced
death
fig
signific
differ
febril
ill
weight
loss
observ
control
treatment
group
fig
c
nhp
mild
reduct
activ
respons
day
postexposur
sever
decreas
observ
anim
day
postexposur
tabl
loss
appetit
lymphadenopathi
began
day
follow
dehydr
rash
petechi
maculopapular
day
postexposur
clinic
sign
differ
significantli
group
plasma
viremia
quantifi
rtqpcr
viral
titer
determin
plaqu
assay
viral
rna
first
detect
serum
anim
day
exposur
rapid
substanti
increas
day
placebo
aqtreat
anim
rna
level
necropsi
rang
viral
rna
copiesml
nhp
fig
infecti
viral
titer
follow
similar
trend
group
sharp
increas
viral
titer
start
day
postexposur
reach
peak
plateau
day
anim
death
fig
viremia
correl
onset
clinic
sign
diseas
loss
appetit
lymphadenopathi
fever
aq
treatment
reduc
plasma
viral
rna
copi
infecti
viru
titer
regardless
treatment
initi
signific
differ
viral
titer
observ
group
anim
show
similar
hematolog
profil
regardless
treatment
complet
blood
count
serum
chemistri
analysi
perform
schedul
sampl
point
day
day
necropsi
exposur
fig
chemistri
valu
aqtreat
nhp
follow
trend
control
anim
valu
similar
hematolog
biochem
profil
observ
anim
regardless
treatment
aq
placebotr
anim
concurr
neutrophilia
thrombocytopenia
observ
aq
placebotr
anim
day
postexposur
ebov
fig
anim
reach
endpoint
criteria
neutrophil
level
decreas
fig
lowlevel
neutrophil
valu
day
postexposur
necropsi
sampl
nhp
treatment
group
exhibit
concomit
increas
serum
creatinin
blood
urea
nitrogen
level
indic
renal
dysfunct
often
note
nhp
concurr
evd
fig
biochem
abnorm
consist
evd
also
observ
begin
day
postexposur
includ
substanti
elev
serum
alt
ast
gammaglutamyl
transpeptidas
ggt
level
indic
hepatocellular
damag
fig
e
f
necropsi
perform
anim
evalu
patholog
diseas
associ
ebov
infect
follow
aq
placebo
treatment
pathologist
blind
group
identif
necropsi
tissu
evalu
patholog
find
similar
type
sever
treat
untreat
anim
gross
histopatholog
find
anim
consist
typic
evd
rhesu
macaqu
common
gross
find
includ
cutan
rash
face
often
extend
region
bodi
dehydr
discolor
liver
increas
friabil
turgid
spleen
enlarg
often
congest
kidney
microscop
level
anim
exhibit
lymphoid
deplet
axillari
lymph
node
lymphoid
deplet
necrosi
spleen
hepatocellular
degener
necrosi
pannicul
necrosi
observ
viru
challeng
site
anim
gammairradi
plasma
sampl
infect
anim
collect
day
postexposur
day
necropsi
day
analyz
determin
plasma
level
aq
metabolit
deaq
data
indic
neglig
level
aq
five
plasma
sampl
differ
anim
day
fig
sampl
dilut
factor
decontamin
protocol
concentr
like
limit
detect
plasma
level
metabolit
deaq
higher
aq
detect
treat
anim
group
fig
deaq
evid
day
postexposur
andor
necropsi
anim
group
anim
group
plasma
level
deaq
ebovinfect
nhp
compar
differ
time
point
fig
anim
treat
day
group
fig
plasma
deaq
level
rang
ngml
day
postexposur
highest
deaq
level
detect
necropsi
sampl
day
ngml
anim
treat
day
postexposur
group
fig
plasma
concentr
rang
ngml
day
higher
concentr
detect
day
ngml
day
postexposur
ngml
plasma
level
deaq
infect
nhp
healthi
nhp
compar
select
time
point
ident
pk
efficaci
studi
plasma
sampl
infect
group
anim
day
correspond
pkplasma
sampl
taken
h
dose
healthi
anim
higher
plasma
level
deaq
ngml
infect
anim
ngml
fig
similarli
plasma
sampl
day
infect
group
anim
lower
rang
n
ngml
healthi
anim
correspond
time
point
h
dose
n
ngml
fig
day
h
dose
deaq
level
plasma
two
anim
group
similar
rang
n
ngml
found
healthi
anim
n
ngml
fig
repurpos
drug
continu
interest
healthcar
profession
commun
treatment
emerg
reemerg
hemorrhag
fever
virus
ebola
marburg
lassa
virus
extens
effort
screen
approv
establish
drug
antivir
activ
led
panel
drug
broadspectrum
antivir
activ
profil
avail
afford
wellcharacter
pksafeti
profil
could
use
emerg
use
author
eua
number
fdaapprov
compound
proven
efficaci
ebov
vitro
murin
model
diseas
clinic
evalu
evalu
relev
diseas
model
nhp
limit
aq
wellknown
antimalari
drug
wide
usag
countri
experi
outbreak
evd
drug
activ
sever
human
pathogen
viru
famili
includ
corona
flavi
recent
report
show
entri
lassagp
pseudotyp
viru
block
aq
indic
drug
may
also
valu
treatment
viral
hemorrhag
aq
known
vitro
antivir
activ
multipl
mechan
antivir
activ
propos
aq
may
block
ebov
entri
depend
acidif
endosom
cation
amphiphil
drug
aq
accumul
late
endolysosom
weak
base
neutral
acid
environ
therebi
inhibit
cathepsin
b
activ
requir
fusion
viral
endosom
aq
also
report
bind
inhibit
cathepsin
b
silico
bind
studi
reveal
aq
may
also
bind
viral
protein
found
aq
inhibit
ebov
replic
multipl
cell
type
includ
huh
vero
cell
primari
human
macrophag
rang
um
depend
experi
cell
type
tabl
aq
rapidli
metabol
activ
metabolit
deaq
follow
oral
administr
vitro
studi
confirm
activ
metabolit
also
antiebov
properti
huh
vero
cell
primari
human
macrophag
rang
depend
experi
cell
type
contrast
metabolit
dha
demonstr
minim
vitro
antivir
activ
ebov
test
sidebysid
aq
use
assay
paramet
use
combin
aq
synergist
effect
ebov
replic
vitro
wherea
could
possibl
act
aq
impact
whole
bodysystem
respons
ebov
way
replic
vitro
assay
studi
assum
aq
main
contribut
factor
drug
combin
result
antiebov
activ
goal
studi
treat
anim
aq
use
similar
dose
strategi
human
patient
target
blood
concentr
rang
parent
compound
aq
inde
found
mgkg
aq
dose
use
treatment
regimen
result
correl
plasma
level
ngml
healthi
nhp
howev
treatment
regimen
result
surviv
benefit
decreas
diseas
symptom
ebovinfect
anim
result
disappoint
highlight
import
util
relev
anim
model
evd
evalu
potenti
antivir
includ
detail
character
pharmacokinet
toler
context
evd
wherea
aq
treatment
lead
detect
benefici
effect
evd
progress
nhp
may
valu
investig
novel
aq
deriv
improv
antiebov
potenc
andor
improv
possibl
impact
aq
side
effect
need
consid
rare
instanc
acut
liver
injuri
usual
prolong
treatment
reason
aq
combin
drug
asaq
recommend
use
malaria
treatment
endem
area
prophylaxi
malaria
onset
hepat
injuri
often
associ
agranulocytosi
elev
liver
enzym
alt
ast
observ
healthi
nhp
pharmacokinet
studi
given
evd
patient
given
coformul
aq
would
interest
test
combin
regimen
rather
aq
evalu
potenti
implic
two
drug
diseas
progress
wherea
measur
antiebov
effect
test
combin
aq
vitro
drug
could
vivo
effect
captur
cell
cultur
assay
artemeth
deriv
artemisinin
metabol
dha
activ
metabolit
treatment
malaria
howev
water
solubl
reach
peak
concentr
rapidli
higher
plasma
cmax
artemeth
could
impact
vivo
activ
ebov
anoth
consider
aq
may
affect
term
pk
drug
metabol
disposit
exampl
coadministr
aq
report
reduc
exposur
question
remain
possibl
contribut
benefici
effect
asaq
treatment
observ
evd
therefor
test
coformul
would
valu
without
test
drug
singli
well
attribut
observ
effect
specif
compon
challeng
confound
factor
measur
gignoux
studi
could
account
benefici
effect
potenti
impact
concurr
malaria
type
antimalari
use
evd
patient
address
studi
conclus
treatment
aq
benefici
effect
surviv
symptom
evd
rhesu
macaqu
condit
test
wherea
aq
fail
demonstr
efficaci
exclud
potenti
therapeut
valu
aq
use
combin
anoth
antivir
anim
studi
conduct
facil
accredit
associ
assess
accredit
laboratori
anim
care
intern
aaalac
approv
either
institut
anim
care
use
committe
iacuc
sri
intern
nation
institut
allergi
infecti
diseas
divis
clinic
research
complianc
anim
welfar
act
regul
public
health
servic
polici
guid
care
use
laboratori
anim
recommend
work
infecti
ebov
potenti
infecti
materi
deriv
anim
conduct
biosafeti
level
bsl
laboratori
integr
research
facil
nation
institut
allergi
infecti
diseas
niaid
fort
detrick
md
vero
atcc
manassa
va
hela
atcc
huh
human
hepatocellular
carcinoma
cell
maintain
follow
recommend
protocol
human
monocytederiv
macrophag
mdm
gener
previous
ebola
ebovmak
genbank
access
propag
vero
cell
bei
resourc
niaid
nih
vero
african
green
monkey
kidney
work
bank
previous
viru
stock
challeng
inoculum
titer
determin
plaqu
assay
vero
cell
previous
vitro
studi
antimalari
artesunateamodiaquin
asaq
winthrop
sanofiaventi
gentilli
cedex
franc
solubil
crush
tablet
resuspend
dimethyl
sulfoxid
prepar
solut
aq
compon
concentr
mm
compound
amodiaquin
dihydrochlorid
dihydr
artesun
dihydroartemisinin
purchas
sigmaaldrich
saint
loui
mo
ndesethylamodiaquin
hydrochlorid
obtain
santa
cruz
biotechnolog
dalla
tx
drug
prepar
mm
stock
dimethyl
sulfoxid
anim
studi
sourc
formul
prepar
amodiaquin
hydrochlorid
pk
efficaci
studi
amodiaquin
hydrochlorid
obtain
us
pharmacopeia
rockvil
md
cat
lot
mgml
aq
free
base
solut
prepar
steril
water
inject
usp
cellbas
ebov
drug
screen
cytotox
assay
perform
previous
briefli
vero
huh
cell
seed
cellswel
mdm
cellswel
plate
h
cell
treat
compound
dilut
start
start
concentr
asaq
tablet
suspens
correspond
aq
base
compon
cell
infect
ebovmak
h
addit
drug
biosafeti
level
contain
multipl
infect
moi
h
plate
fix
neutral
buffer
formalin
richardallan
scientif
ebovmak
detect
mous
antibodi
specif
ebov
protein
usamriid
follow
stain
alexa
goat
antimous
igg
heavi
light
chain
antibodi
life
technolog
grand
island
ny
antimous
iggperoxidas
label
antibodi
kpl
fluoresc
luminesc
quantifi
plate
reader
pro
tecan
us
morrisvil
nc
signal
treat
infect
well
normal
uninfect
control
well
measur
percent
rel
untreat
infect
well
nonlinear
regress
analysi
perform
inhibitori
concentr
calcul
fit
curv
log
agonist
versu
respons
variabl
slope
constraint
remain
graphpad
softwar
la
jolla
ca
ebov
drug
screen
assay
perform
three
replic
drug
concentr
assay
repeat
least
twice
confirm
evalu
cytotox
cell
treat
compound
describ
absenc
viru
h
drug
addit
cell
viabil
quantifi
use
celltit
glo
luminesc
cell
viabil
assay
kit
promega
madison
wi
rhesu
macaqu
macaca
mulatta
obtain
covanc
research
product
princeton
nj
two
group
n
femal
male
per
group
dose
mgkg
amodiaquin
hydrochlorid
us
pharmacopeia
rockvil
md
cat
lot
oral
via
nasogastr
intub
daili
day
nhp
hous
stainless
steel
primari
enclosur
singli
pair
compat
nhp
provid
teklad
certifi
global
protein
primat
diet
purifi
water
ad
libitum
clinic
observ
conduct
day
includ
day
dose
blood
maxim
collect
cephal
vessel
day
day
day
blood
collect
predos
h
postdos
immedi
prior
dose
day
day
blood
collect
h
dose
h
dose
immedi
prior
dose
day
h
dose
drug
concentr
aq
metabolit
deaq
determin
collect
plasma
sampl
use
liquid
chromatographi
tandem
mass
spectrometri
lcmsm
plasma
sampl
volum
prepar
ad
ml
methyl
tbutyl
ether
tube
vortex
approxim
minut
min
maxim
speed
centrifug
min
g
facilit
separ
liquid
phase
upper
layer
transfer
new
tube
solvent
remov
vacuum
centrifug
evapor
dri
residu
reconstitut
intern
standard
solut
ngml
risperidon
ngml
chloroquin
v
v
acetonitril
water
tube
vortex
min
clarifi
centrifug
g
min
clarifi
extract
transfer
high
perform
liquid
chromatographi
vial
contain
glass
insert
subsequ
lcmsm
analysi
lcmsm
perform
use
pump
system
shimadzu
columbia
md
qtrap
mass
spectromet
sciex
concord
ontario
canada
multipl
reaction
monitor
mode
polari
column
mm
agil
ca
use
gradient
elut
formic
acid
water
formic
acid
acetonitril
mobil
phase
lower
limit
quantit
aq
deaq
method
ngml
follow
paramet
constant
determin
maxim
plasma
concentr
cmax
time
maximum
plasma
concentr
tmax
area
plasma
concentrationtim
curv
last
time
point
extrapol
infin
auclast
aucinf
termin
elimin
halflif
appar
volum
distribut
vf
total
clearanc
clf
oral
administr
pk
paramet
analyz
use
softwar
v
certara
princeton
nj
perform
noncompartment
data
analysi
extravascular
administr
clinic
patholog
serum
chemistri
hematolog
blood
ml
collect
prior
dose
day
approxim
h
final
day
dose
rhesu
macaqu
chines
origin
n
adult
year
age
obtain
charl
river
laboratori
frederick
md
anim
singli
hous
stainless
steel
primari
enclosur
provid
chow
purifi
revers
osmosi
water
ad
libitum
vehicl
control
group
group
n
treat
steril
water
two
treatment
group
treat
aq
oral
daili
consecut
cours
mgkg
free
base
mgkg
amodiaquin
hydrochlorid
us
pharmacopeia
rockvil
md
cat
lot
treatment
began
day
ebov
exposur
group
n
femal
male
day
postexposur
group
n
femal
male
group
challeng
im
target
dose
pfu
ebovmak
actual
dose
pfu
plaqu
assay
backtitr
challeng
materi
initi
day
prepar
studi
day
vero
cell
plaqu
fix
formalin
stain
crystal
violet
day
later
anim
observ
weigh
daili
vehicl
control
group
group
n
receiv
equival
volum
steril
water
gibco
cat
lot
weight
record
day
day
daili
start
one
day
challeng
primat
succumb
diseas
respons
anim
monitor
follow
rang
score
met
primari
endpoint
criteria
initi
secondari
criteria
evalu
tabl
nhp
score
primari
euthanasia
criteria
temperatur
secondari
euthanasia
criteria
review
nhp
meet
least
two
secondari
criteria
blood
urea
nitrogen
mgdl
calcium
mgdl
ggt
udl
andor
creatinin
mgdl
requir
euthanasia
two
rhesu
macaqu
euthan
base
secondari
criteria
six
fifteen
rhesu
macaqu
euthan
base
veterinari
discret
base
clinic
score
secondari
criteria
complet
blood
count
leukocyt
differenti
perform
peripher
collect
blood
sampl
use
vacuett
ethylenediaminetetraacet
acid
edta
tube
sysmex
hematolog
instrument
use
preprogram
monkey
speci
profil
sysmex
america
ny
plasma
serum
prepar
separ
min
ambient
temperatur
centrifug
set
rcf
serum
chemistri
perform
use
piccolo
xpress
analyz
gener
chemistri
disc
abaxi
abbott
point
care
nj
vacuett
z
serum
clot
activ
tube
greiner
bioon
monro
nc
anim
human
euthanat
accord
defin
experiment
endpoint
gross
necropsi
perform
tissu
sampl
inactiv
fix
h
neutral
buffer
formalin
follow
fixat
remov
laboratori
accord
standard
oper
procedur
tissu
sampl
routin
process
tissuetek
autom
vacuum
infiltr
processor
sakura
finetek
usa
torranc
california
usa
follow
paraffin
embed
tissuetek
model
tec
unit
sakura
finetek
usa
torranc
ca
usa
use
standard
semiautom
rotari
microtom
light
water
flotat
bath
leica
biosystem
wetzlar
germani
tissu
section
cut
thick
mount
posit
charg
uncoat
glass
slide
thermofish
waltham
usa
airdri
room
temperatur
stain
hematoxylin
eosin
h
e
coverslip
microscop
evalu
pathologist
plasma
inactiv
trizol
ls
thermofish
scientif
waltham
total
rna
isol
use
qiaamp
viral
rna
mini
kit
qiagen
germantown
md
accord
manufactur
instruct
briefli
trizol
lsinactiv
sampl
ad
qiagen
buffer
avl
contain
carrier
rna
sampl
elut
buffer
ave
aliquot
frozen
assay
plasma
viral
rna
quantifi
use
bei
resourc
critic
reagent
program
rtqpcr
taqman
assay
kit
abi
fastdx
appli
biosystem
thermofish
scientif
accord
manufactur
instruct
use
synthet
rna
standard
curv
report
viral
rna
copi
per
ml
sampl
plasma
sampl
dilut
dulbecco
modifi
eagl
medium
glutamax
gibco
hifb
gibco
ad
confluent
monolay
vero
cell
triplic
sampl
adsorb
cell
monolay
h
gentl
rock
approxim
everi
min
prevent
monolay
dri
monolay
overlaid
mix
avicel
rc
biopolym
fmc
biopolym
mix
modifi
eagl
medium
temin
modif
gibco
supplement
antibioticantimycot
gibco
glutamax
hifb
cell
incub
day
stain
fix
aqueou
gentian
violet
ricca
chemic
neutral
buffer
formalin
min
rins
plaqu
enumer
plasma
sampl
rhesu
macaqu
receiv
dose
aq
integr
research
facilityniaid
fort
detrick
md
analyz
concentr
aq
metabolit
deaq
prior
shipment
sri
sampl
dilut
irradi
mrad
use
sourc
destroy
pathogen
may
present
plasma
sampl
pilot
studi
spike
qualiti
control
standard
confirm
irradi
appreci
alter
level
aq
plasma
data
shown
liquid
liquid
extract
method
methyl
tbutyl
ether
use
separ
aq
deaq
rhesu
macaqu
plasma
sampl
analyz
lcmsm
lower
limit
quantit
lloq
ngml
ngml
dilut
factor
plasma
aq
deaq
aq
deaq
concentr
adjust
dilut
factor
analysi
fig
